Recent advances in search of oral heparin therapeutics

Medicinal Research Reviews

Volumn 32, Issue 2, 2012, Pages 388-409

  Paliwal, Rishi ^a   Paliwal, Shivani R ^a   Agrawal, Govind P ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Bioavailability; Heparin; Novel drug delivery systems; Oral delivery

Indexed keywords

18 BETA GLYCYRRHETINIC ACID; BLOOD CLOTTING FACTOR 10A; CHITOSAN; DECANOATE SODIUM; DEOXYCHOLIC ACID; ENOXAPARIN; FONDAPARINUX; GLUTATHIONE; HEPARIN; HEXAPEPTIDE; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; N SULFONATO N, O CARBOXYMETHYLCHITOSAN; NANOSHELL; PENETRATION ENHANCING AGENT; POLYCAPROLACTONE; POLYGLACTIN; TRIOCTANOIN; UNCLASSIFIED DRUG; ZONULA OCCLUDENS TOXIN;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; GASTROINTESTINAL TRACT; HUMAN; LUNG EMBOLISM; MICROEMULSION; MOLECULAR SIZE; MOLECULAR WEIGHT; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; PATIENT COMPLIANCE; PHYSICOCHEMICAL PHENOMENA;

EID: 84857685980     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20217     Document Type: Article

References (74)

1. Arbit E, Goldberg M, Gomez-Orellana I, Majuru S. Oral heparin: Status review. Thromb J 2006;4:1-7.
2. Hiebert LM. Oral heparins. Clin Lab 2002;48:111-116.
3. Arnold J, Ahsan F, Meezan E, Pillion DJ. Nasal administration of low molecular weight heparin. J Pharm Sci 2002;91:1707-1714.
4. Bai S, Ahsan F. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin. Pharm Res 2009;26:539-548.
5. Jaques LB. Heparins: Anionic polyelectrolyte drugs. Pharmacol Rev 1979;31:99-166.
6. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight-heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
7. Dunn JM, Hollister AS. Oral bioavailability of heparin using a novel delivery system. Curr Ther Res 1995;56:738-745.
8. Hoffart V, Ubrich N, Lamprecht A, Bachelier K, Vigneron C, Lecompte T, Hoffman M, Maincent P. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv 2003;10:1-7.
9. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006;113:38-42.
10. Lee Y, Kim SH, Byun Y. Oral delivery of new heparin derivatives in rats. Pharm Res 2000;17:1259-1264.
11. Lee Y, Nam JH, Shin HC, Byun Y. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent. Circulation 2001;104:3116-3120.
12. Lee YK, Kim SK, Lee DY, Lee S, Kim CY, Shin HC, Moon HT, Byun Y. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J Control Release 2006;111:290-298.
13. Lee DY, Lee J, Lee S, Kim SK, Byun Y. Liphophilic complexation of heparin based on bile acid for oral delivery. J Control Release 2007;123:39-45.
14. 13C NMR spectroscopy. Macromolecules 1979;12:1001-1007.
15. Bentolila A, Vlodavsky I, Haloun C, Domb AJ. Synthesis and heparin-like biological activity of amino acid-based polymers. Polym Adv Technol 2000;11:377-387.
16. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci 1997;94:14683-14688.
17. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci 2001;98:3352-3357.
18. Borsig L. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol Sci 2004;19:16-21.
19. Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG. Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging 2002;23:531-536.
20. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 2004;24:4181-4186.
21. Perretti M, Page CP. Heparin and inflammation: A new use for an old GAG? Gut 2000;47:14-15.
22. Linhardt RJ. Heparin-induced cancer cell death. Chem Biol 2004;11:420-422.
23. Lam LH, Silbert JE, Rosenberg RD. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976;69:570-577.
24. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976;9:575-583.
25. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982;257:2162-2169.
26. Weitz JI, Young E, Johnston M, Stafford AR, Fredenburgh JC, Hirsh J. Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation 1999;99:682-689.
27. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004;110:119-126.
28. Medina RP, Foto D. The use of bivalirudin to prevent subacute thrombosis during drug-eluting stent implantation. J Invasive Cardiol 2004;16:236-239.
29. Wang HJ, Lin ZX, Liu XM, Sheng SY, Wang JY. Heparin-loaded zein microsphere film and hemocompatibility. J Control Release 2005;105:120-131.
30. Hwang CW, Wu DER. Edelman, physiological transport forces govern drug distribution for stent based delivery. Circulation 2001;104:600-605.
31. Whelan DM, van Beusekom HM, van der Giessen WJ. Mechanisms of drug loading and release kinetics. Semin Interv Cardiol 1998;3:127-131.
32. Thomas AC, Campbell JH. Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. Atherosclerosis 2004;176:73-81.
33. Park YJ, Liang JF, Song H, Li YT, Naik S, Yang VC. ATTEMPTS: A heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv Drug Deliv Rev 2003;55:251-265.
34. Motlekar NA, Youan BB. The quest for non-invasive delivery of bioactive macromolecules: A focus on heparins. J Control Release 2006;113:91-101.
35. Windsor E, Freeman L. An investigation of routes of administration of heparin other than injection. Am J Med 1964;37:408-416.
36. Malkov D, Huai-zhen W, Dinh S, Gomez-Orellana I. Pathway of oral absorption of heparin with sodium N-[8-(2 hydroxybenzoyl) amino]caprylate. Pharm Res 2002;19:1180-1184.
37. Ross BP, Toth I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr Drug Deliv 2005;2:277-287.
38. Dal Pozzo A, Acquasaliente M, Geron MR. New heparin complexes active by intestinal absorption: I. Multiple ion pairs with basic organic compounds. Thromb Res 1989;56:119-124.
39. Money SR, York JW. Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc Surg 2001;9:211-218.
40. Mark DG, Jeffrey DM, Andrea LB. Orally administered heparin for preventing deep venous thrombosis. Am J Surg 1998;176:176-178.
41. Rivera TM, Leone-Bay A, Paton DR, Leipold HR, Baughman RA. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations. Pharm Res 1997;14:1830-1834.
42. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella-Lawson F, FitzGerald GA. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 1998;98:1610-1615.
43. Salartash K, Gonze MD, Leone-Bay A, Baughman R, Sternbergh WC, 3rd, Money SR. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J Vasc Surg 1999;30:526-531.
44. Salartash K, Lepore M, Gonze MD, Leone-Bay A, Baughman R, Sternbergh WC, 3rd, Bowen JC, Money SR. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Ann Surg 2000;231:789-794.
45. Leone-Bay A, Paton DR, Variano B, Leipold H, Rivera T, Miura-Fraboni J, Baughman RA, Santiago N. Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium USP. J Control Release 1998;50:41-49.
46. Leone-Bay A, Paton DR, Freeman J, Lercara C, O'Toole D, Gschneidner D, Wang E, Harris E, Rosado C, Rivera T, DeVincent A, Tai M, Mercogliano F, Agarwal R, Leipold H, Baughman RA. Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin. J Med Chem 1998;41:1163-1671.
47. Hayes PY, Ross BP, Thomas BG, Toth I. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg Med Chem 2006;14:143-152.
48. Bernkop-Schnürch A, Kast CE, Guggi D. Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/GSH systems. J Control Release 2003;93:95-103.
49. Bernkop-Schnürch A, Hoffer MH, Kafedjiiski K. Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin Drug Deliv 2004;1:87-98.
50. Kast CE, Guggi D, Langoth N, Bernkop-Schnürch A. Development and in vivo evaluation of an oral delivery system for low molecular weight heparin based on thiolated polycarbophil. Pharm Res 2003;20:931-936.
51. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target 2005;13:573-583.
52. Motlekar NA, Fasano A, Wachtel MS, Youan BB. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin. J Drug Target 2006;14:321-329.
53. Thanou M, Henderson S, Kydonieus A, Elson C. N-Sulfonato-N, O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release 2007;117:171-178.
54. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev Res 2006;67:166-174.
55. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, Maincent P. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105:230-235.
56. Chandy T, Rao GH, Wilson RF, Das GS. Delivery of LMW heparin via surface coated chitosan/peg-alginate microspheres prevents thrombosis. Drug Deliv 2002;9:87-96.
57. Schmitz T, Leitner VM, Bernkop-Schnürch A. Oral heparin delivery: Design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system. J Pharm Sci 2005;94:966-973.
58. Meissner Y, Ubrich N, El Ghazouani F, Maincent P, Lamprecht A. Low molecular weight heparin loaded pH-sensitive microparticles. Int J Pharm 2007;335:147-153.
59. Lamprecht A, Ubrich N, Maincent P. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur J Pharm Biopharm 2007;67:632-638.
60. Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP. Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm 2009;380:181-188.
61. Kim SK, Lee EH, Vaishali B, Lee S, Lee YK, Kim CY, Moon HT, Byun Y. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates. J Control Release 2005;105:32-42.
62. Lanke SS, Gayakwad SG, Strom JG, D'souza MJ. Oral delivery of low molecular weight heparin microspheres prepared using biodegradable polymer matrix system. J Microencapsul 2009;26:493-500.
63. Chen MC, Wong HS, Lin KJ, Chen HL, Wey SP, Sonaje K, Lin YH, Chu CY, Sung HW. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 2009;30:6629-6637.
64. Ito Y, Kusawake T, Prasad YV, Sugioka N, Shibata N, Takada K. Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. Int J Pharm 2006;317:114-119.
65. Kim SK, Vaishali B, Lee E, Lee S, Lee YK, Kumar TS, Moon HT, Byun Y. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res 2006;117:419-427.
66. Kim SK, Lee DY, Lee E, Lee YK, Kim CY, Moon HT, Byun Y. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release 2007;120:4-10.
67. Leonard TW, Lynch J, McKenna MJ, Brayden DJ. Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv 2006;3:685-692.
68. Leone-Bay A, Paton DR, Weidner JJ. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med Res Rev 2000;20:169-186.
69. Pineo GF, Hull RD, Marder V. Orally active heparin and low-molecular-weight heparin. J Curr Opin Pulm Med 2001;7:344-348.
70. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov 2003;2:289-295.
71. Pineo G, Hull R, Marder V. Oral delivery of heparin: SNAC and related formulations. Best Pract Res Clin Haematol 2004;17:153-160.
72. Berkowitz SD, Marder VJ, Kosutic G, Baughman RA. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J Thromb Haemost 2003;1:1914-1919.
73. Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007;321:726-733.
74. Dufresne MH, Leroux JC. Study of the micellization behavior of different order amino block copolymers with heparin. Pharm Res 2004;21:160-169.